Endogenous Canine FIX Antigen Exists in Chapel Hill Strain Hemophilia B Canine

References
1 Brinkhous K, Sigman J, Read M, Stewart P, McCarthy K, Timony G, Leppanen S, Rup B, Keith JJ, Garzone P, Schaub R. Recombinant human factor IX: replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B. Blood 1996; 88 (07) 2603-10.
2 Chao H, Samulski R, Bellinger D, Monahan P, Nichols T, Walsh C. Persistent expression of canine factor IX in hemophilia B canines. Gene Therapy 1999 in press.
3 Herzog R, Yang E, Couto L, Hagstrom N, Elwell D, Field P, Burton M, Bellinger D, Read M, Brinkhous K, Podsakoff G, Nichols T, Kurtzman G, High K. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nature Medicine 1999; 5 (01) 56-63.
4 Monahan P, Samulski R, Tazelaar J, Xiao X, Nichols T, Bellinger D, Read M, Walsh C. Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia. Gene Therapy 1998; 5 (01) 40-9.
5 Snyder R, Miao C, Meuse L, Tubb J, Donahue B, Lin H, Stafford D, Patel S, Thompson A, Nichols T, Read M, Bellinger D, Brinkhous K, Kay M. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nature Medicine 1999; 5 (01) 64-70.
6 Evans J, Brinkhous K, Brayer G, Reisner H, High K. Canine hemophilia B resulting from a point mutation with unusual consequences. Proc Natl Acad Sci USA 1989; 86 (24) 10095-9.
7 High K. Factor IX: molecular structure, epitopes, and mutations associated with inhibitor formation. in: Inhibitors to coagulation factors. Aledort L.. et al., Editors New York: 1995. Lenum Press; 79-86.
8 Sugahara Y, Catalfamo J, Brooks M, Hitomi E, Bajaj S, Kurachi K. Isolation and characterization of canine factor IX. Thromb Haemost 1996; 75 (03) 450-5.